Clinical Trial Detail

NCT ID NCT02029417
Title Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Roswell Park Cancer Institute
Indications

acute myeloid leukemia

Therapies

Cytarabine + Decitabine + Omacetaxine mepesuccinate

Age Groups: senior

No variant requirements are available.